Conferences - Results from #7400

ASCO 2018: The Association of BRCA1 and BRCA2 Mutations on Prostate Cancer Risk, Frequency, and Mortality: Systematic Review and Meta-Analysis June 5, 2018

ASCO 2018: Role of Surgery in Management of High-Risk Renal Cell Cancer June 4, 2018

ASCO 2018: Systemic Therapy in Management of High-Risk Renal Cancer June 4, 2018

ASCO 2018: Multicenter Randomized Phase 2 Trial of Paclitaxel, Ifosfamide, and Cisplatin Versus Bleomycin, Etoposide, and Cisplatin for First-line Treatment of Patients with Intermediate- or Poor-risk Germ Cell Tumors June 4, 2018

ASCO 2018: The GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer in Washington State and Beyond June 4, 2018

ASCO 2018: Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide June 4, 2018

ASCO 2018: Subsequent Treatment after Abiraterone Acetate + Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-naïve Prostate Cancer: LATITUDE June 4, 2018

ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort June 4, 2018

ASCO 2018: SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US June 4, 2018

ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry June 4, 2018

ASCO 2018: Bladder Cancer and Germ Cell Tumors June 4, 2018

ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward June 4, 2018

ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy? June 4, 2018

ASCO 2018: Nonimmunotherapy Strategies in Advanced Bladder Cancer June 4, 2018

ASCO 2018: Radiopharmaceuticals: Emitting the Right Signals in Prostate Cancer June 4, 2018

ASCO 2018: Science of Oncology Award Lecture: Preventing HPV-Associated Cancers by Vaccination June 4, 2018

ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma June 4, 2018

ASCO 2018: Patient-reported Outcomes in IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Treatment Naive mRCC June 4, 2018

ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy June 4, 2018

ASCO 2018: Abiraterone Acetate and Prednisone, AAP Plus Degarelix, and Degarelix Alone for Patients with Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy June 4, 2018

Page 371 of 589